

Referenzen

1. Facon T et al. N Engl J Med 2019;380:2104–2115.
2. Kumar SK et al., Updated Analysis of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) versus Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-ineligible Newly Diagnosed Multiple Myeloma (NDMM), Poster 2276 presented at ASH; 5–8 December, 2020, online.